PNAS Publishes Preclinical Results of EntreMed's 2ME2 for Multiple Sclerosis

 PNAS Publishes Preclinical Results of EntreMed's 2ME2 for Multiple Sclerosis

PR Newswire

ROCKVILLE, Md., Dec. 4, 2012

ROCKVILLE, Md., Dec. 4, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a
clinical-stage pharmaceutical company developing therapeutics for the
treatment of cancer, announced today that preclinical results for its compound
2-methoxyestradiol (2ME2) were published on line in this week's Early Edition
of Proceedings of the National Academy of Sciences (PNAS). The study was
conducted at The Campbell Family Institute for Breast Cancer Research at
Princess Margaret Hospital and was led by Tak W. Mak, Ph.D.

(Logo: )

Tak W. Mak, Ph.D., Director, The Campbell Family Cancer Research Institute,
commented on the study, "Multiple sclerosis (MS) is among the most common
autoimmune disorders in the northern hemisphere. There exists significant
unmet medical need for safe and effective drugs to treat MS. In this study,
we demonstrated that 2ME2, an endogenous metabolite of estradiol,
significantly inhibits lymphocyte activation and proliferation and
dramatically suppresses development of experimental MS. Our analysis of
cellular signaling pathways further reveals that 2ME2 exerts a potent
inhibition of Nuclear Factor of Activated T cells (NFAT). By extension, the
study provides for the first time a molecular rational for the use of 2ME2 as
a tolerable oral immunomodulatory agent for autoimmune disorders such as MS.
Other studies have shown that in humans, plasma levels of 2ME2 may increase
dramatically during the last months of pregnancy, which intriguingly appears
to correlate temporally with the remission of clinical symptoms reported in
some pregnant MS and rheumatoid arthritis (RA) patients. We believe that 2ME2
may offer a safe and effective treatment for such autoimmune disorders."

Ken Ren, Ph.D., EntreMed's Chief Executive Officer further commented, "In
addition to ENMD-2076 for oncology, 2ME2 represents another important asset
for our company with its strong IP position and sound safety profile.
Together with our previous findings of its disease modifying activity in RA
animal models, this study further extends 2ME2's therapeutic value to the
management of MS, RA and possibly other autoimmune disorders."

Dr. Ren continued, "We appreciate the international recognition by our peers.
For the next step, we intend to further advance 2ME2 development as part of
our global drug development plan and strategy to leverage resources both in
the US and China. We are currently exploring multiple strategies for the
development of 2ME2 including possible partnership opportunities. We believe
that the development of 2ME2 for autoimmune diseases fits well with our plan
to build a robust product pipeline and to add value for our long term

The article is entitled "2-Methoxyestradiol inhibits experimental autoimmune
encephalomyelitis through suppression of immune cell activation" and was
authored by Gordon S. Duncan, Dirk Brenner, Michael W. Tusche, Anne Brustle,
Christiane B. Knobbe, Andrew J. Elia, Thomas Mock, Mark R. Bray, Peter H.
Krammer and Tak W. Mak. The article is available at

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company employing a drug
development strategy primarily in the United States and China to develop
targeted therapeutics for the global market. Its lead compound, ENMD-2076, a
selective Aurora A and angiogenic kinase inhibitor for cancer, has completed
several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and
is currently completing a multi-center Phase 2 study in ovarian cancer.
EntreMed, Inc. recently initiated a dual-institutional Phase 2 study of
ENMD-2076 in triple-negative breast cancer. Its second compound, 2ME2, has
been investigated in clinical trials in oncology patients, and is the subject
of a successful IND filing for clinical use to treat RA. Additional
information about EntreMed is available on the Company's web site at
www.entremed.comand in various filings with the Securities and Exchange
Commission (the SEC).

Forward Looking Statements

This release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act with respect to the outlook for
expectations for future financial or business performance, strategies,
expectations and goals. Forward-looking statements are subject to numerous
assumptions, risks and uncertainties, which change over time. Forward-looking
statements speak only as of the date they are made, and no duty to update
forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to
a number of factors, including: the risk that we may be unable to continue as
a going concern as a result of our inability to raise sufficient capital for
our operational needs; the possibility that we may be delisted from trading on
the Nasdaq Capital Market; the volatility of our common stock; the difficulty
of executing our business strategy in China; our inability to enter into
strategic partnerships for the development, commercialization, manufacturing
and distribution of our proposed product candidate; risks relating to the need
for additional capital and the uncertainty of securing additional funding on
favorable terms; declines in actual sales of Thalomid^® resulting in reduced
royalty payments; risks associated with our product candidates; any
early-stage products under development; results in preclinical models are not
necessarily indicative of clinical results; uncertainties relating to
preclinical and clinical trials, including delays to the commencement of such
trials; the lack of success in the clinical development of any of our
products; dependence on third parties; and risks relating to the
commercialization, if any, of our proposed products (such as marketing,
safety, regulatory, patent, product liability, supply, competition and other
risks). Such factors, among others, could have a material adverse effect upon
our business, results of operations and financial condition. We caution
readers not to place undue reliance on any forward-looking statements, which
only speak as of the date made. Additional information about the factors and
risks that could affect our business, financial condition and results of
operations, are contained in our filings with the U.S. Securities and Exchange
Commission ("SEC"), which are available at

Investor Relations
EntreMed, Inc.

SOURCE EntreMed, Inc.

Press spacebar to pause and continue. Press esc to stop.